Research programme: antiretrovirals - Mutabilis
Latest Information Update: 26 Jan 2016
At a glance
- Originator Mutabilis
- Class Small molecules
- Mechanism of Action Human immunodeficiency virus protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 25 Jan 2016 Preclinical trials in HIV infections in France (unspecified route) before January 2016